Interview with Tomáš Matějovský, Partner, CMS Cameron McKenna Czech…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Address: CMS Cameron McKenna v.o.s. Palladium, Na Poříčí 1079/3a 110 00 Prague 1,Czech Republic
Tel: +420 296 798-111
Web: http://www.cms-cmck.com/Prague-Czech-Republic
The Prague office of CMS was established in 1991. The office has over 35 international and local lawyers and provides a full range of legal services to both domestic and international clients. We conduct regular independent reviews with clients and these indicate that they value our ability to combine international expertise with local knowledge.
We have significant experience in working with international and local companies, insurers, banks and financial institutions, private organizations and government authorities. CMS in Prague is considered a market leader and our experts, such as Tomáš Matějovský, receive excellent feedback from clients.
CMS Cameron McKenna has a track record of advising lifesciences businesses throughout Central and Eastern Europe. We have been established in the region for more than twenty years, which means we never underestimate the differences between local markets, whilst taking into account EU and EEA standards.
Over the past years sector regulations in the region have undergone significant changes – from the rules on marketing pharmaceutical and healthcare products to legislation relating to medical devices. The changes have had a profound effect on the way business is conducted in CEE. We’ve made it our business to know the market inside out.
Our clients tell us that we have the in-depth knowledge they need to support their businesses across the region. We speak the industry’s language and our cross-regional lifesciences practice comprises 50+ lawyers advising some of the sector’s major players and representatives.
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Ms. Polekova, you established the Celgene affiliate in this country from scratch in 2008. When we spoke to Mr. Victor Ferkovich, your colleague in Russia, he commented on his own…
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here
